Burning Rock Biotech (BNR) EBIAT: 2019-2025
Historic EBIAT for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to $17.6 million.
- Burning Rock Biotech's EBIAT fell 90.83% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.9 million, marking a year-over-year decrease of 107.45%. This contributed to the annual value of -$47.5 million for FY2024, which is 48.42% up from last year.
- Latest data reveals that Burning Rock Biotech reported EBIAT of $17.6 million as of Q3 2025, which was up 182.41% from -$21.3 million recorded in Q2 2025.
- Burning Rock Biotech's 5-year EBIAT high stood at $614.2 million for Q4 2022, and its period low was -$231.5 million during Q3 2022.
- Its 3-year average for EBIAT is $133,364, with a median of -$21.3 million in 2025.
- The largest annual percentage gain for Burning Rock Biotech's EBIAT in the last 5 years was 1,622.01% (2022), contrasted with its biggest fall of 771.09% (2022).
- Quarterly analysis of 5 years shows Burning Rock Biotech's EBIAT stood at -$40.4 million in 2021, then soared by 1,622.01% to $614.2 million in 2022, then slumped by 34.97% to $399.4 million in 2023, then slumped by 102.42% to -$9.7 million in 2024, then crashed by 90.83% to $17.6 million in 2025.
- Its EBIAT stands at $17.6 million for Q3 2025, versus -$21.3 million for Q2 2025 and -$13.5 million for Q1 2025.